Matthew Stotts
Cerulean recently committed to the co-founders of Elio CEO Kami Krista and CTO Kamil Mroczek. Elio provides an AI-powered eco-design software platform that integrates sustainability directly into the process design phase of manufacturing. They are tackling the massive drug development value chain in the pharmaceutical industry with a powerful combination of deep technical insights and close collaboration with commercial partners.
Elio furthers Cerulean’s thesis for investing in systems change through redesigning business processes with nature-positive outcomes by design. Elio joins other powerful sustainable supply-chain companies in Cerulean’s portfolio like CommonShare, Meridia and Epoch.
Our co-investors in the $2M pre-Seed round included Stefan Oschmann (former CEO of Merck) and $200M Munich-based VC, Ananda Impact Ventures.
The Imperative of Eco-Design in the $2.6 Trillion Pharmaceutical Industry
The pharmaceutical industry's commitment to improving human health also creates substantial environmental challenges. Manufacturing processes and early design decisions determine environmental consequences that persist for decades, making sustainable practices crucial from the outset.
Eco-design represents a transformative approach by embedding environmental considerations into product development, where 80% of environmental impact is determined. This proactive strategy enables pharmaceutical companies to address environmental concerns at their source while delivering significant advantages: reduced waste and resource consumption throughout product lifecycles, alongside substantial cost savings in manufacturing and disposal processes.
As the economic advantages of sustainability become increasingly central to business health, companies embracing Elio’s eco-design stand to gain competitive advantages through improved partner relationships and customer loyalty.
Elio: Transforming Pharmaceutical Manufacturing Through Eco-Design
Elio stands at the forefront of this transformation as an essential platform that integrates eco-design directly into pharmaceutical manufacturing processes. With $2M in secured funding, Elio is well-positioned to help scientists and engineers make environmentally conscious decisions from the earliest stages of development. This approach proves particularly valuable in the pharmaceutical industry, where complex stakeholder relationships and stringent regulatory requirements often complicate sustainability initiatives.
Elio's data-driven approach enables companies to begin implementing sustainable practices immediately, rather than waiting for perfect data sets. This pragmatic strategy helps organizations maintain momentum toward their sustainability targets while maximizing cumulative environmental impact.
Elio is going to market through strategic partnerships with industry leaders like Cytiva and ten23 health. Through CEO Kami Krista’s strategic foresight, Elio established the Pharma Eco-design Consortium to foster industry collaboration for sustainable manufacturing solutions, creating more data sharing between pharmaceutical suppliers by approaching it as part of a broader data access management framework.
Industry Partnerships Driving Innovation
ten23 health, a Contract Development and Manufacturing Organisation based in Switzerland, exemplifies the kind of strategic collaboration that advances sustainable pharmaceutical manufacturing. Their partnership with Elio combines scientific expertise with practical industry experience to develop safe, sustainable injectable treatments. Similarly, Cytiva (formerly GE Healthcare Lifesciences) brings global scientific and technological leadership to the initiative. Cytiva’s VP R&D of Sustainable Innovation, Karl Britt, is the working group chair of Elio’s industry consortium.
Systems Change by Understanding Existing System State
Elio has had early success putting pharmaceutical manufacturing on the path to sustainability because the founders’s deep domain expertise and technical experience led them to invest in understanding the state of existing systems in pharmaceutical companies, then collaborating with companies along the value chain to build a comprehensive pathway to integrate eco-design principles into their manufacturing processes. By combining AI-powered software, industry collaboration, and data-driven decision-making, Elio enables pharma companies to embed sustainability into their operations from day one. As the industry moves toward a future where sustainability increasingly equals resilience, Elio stands ready to transform pharmaceutical manufacturing and its supply chains from the ground up.
Stay up to date with Cerulean on LinkedIn, Substack and our Website.
Nothing contained herein constitutes investment, legal, tax or other advice nor is to be relied upon in making an investment or other decision. This article contains the opinions of the author, and such opinions are subject to change without notice. Furthermore, it may also include data and opinions derived from third party sources. Cerulean Ventures does not accept liability for the accuracy or completeness of any such information or opinions which can be subject to change without notice.